Drug intelligence / Profile preview

polycaprolactone microspheres + recombinant type III humanized collagen + sodium hyaluronate

Development stage: Unknown
Lead developer: West China Hospital of Stomatology, Sichuan University
Modality: Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Recombinant Proteins and Enzymes, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
Administration: Intradermal, Subcutaneous

Overview

This drug is an injectable composite dermal filler consisting of polycaprolactone (PCL) microspheres, recombinant type III humanized collagen, and sodium hyaluronate. It is designed for the correction of temporal depression and other facial volume deficits. The PCL microspheres act as a bio-resorbable scaffold that stimulates long-term endogenous collagen production (neocollagenesis) by fibroblasts. The recombinant type III humanized collagen provides immediate, biocompatible structural support and promotes tissue integration and rejuvenation. Sodium hyaluronate serves as a carrier and provides immediate volumization and hydration. This multi-phasic combination aims to provide both immediate aesthetic improvement and sustained tissue regeneration. It is currently being evaluated in Phase 3 clinical trials in China.

Other names: PCL microspheres + recombinant type III humanized collagen-sodium hyaluronate lyophilized fiberPCL-collagen-HA composite filler

Beyond the preview

Go deeper on polycaprolactone microspheres + recombinant type III humanized collagen + sodium hyaluronate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on polycaprolactone microspheres + recombinant type III humanized collagen + sodium hyaluronate.

Explore the full profile